Operating Income (Annual)

Operating Income: The income after operating expenses.

Insight Molecular Diagnostics Inc. (IMDX) had Operating Income of $-51.12M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$4.05M
Net Income	$-50.22M
Cost of Goods Sold	$1.76M
Gross Profit	$2.30M
Operating Expenses	$55.18M
Operating Income	$-51.12M
Non-Operating Income/Expense	$0.90M
Pre-Tax Income	$-50.22M
Normalized Pre-Tax Income	$-50.22M
Income after Taxes	$-50.22M
Income from Continuous Operations	$-50.22M
Consolidated Net Income/Loss	$-50.22M
Normalized Income after Taxes	$-50.22M
EBIT	$-51.12M
EBITDA	$-48.93M
Weighted-Average Shares Outstanding (Basic)	30.48M
Weighted-Average Shares Outstanding (Diluted)	30.48M
Earnings per Share (EPS) (Basic)	$-1.65
Earnings per Share (EPS) (Diluted)	$-1.65
Balance Sheet Financials
Current Assets	$15.31M
Property, Plant, and Equipment	$6.43M
Long-Term Assets	$10.45M
Total Assets	$25.76M
Current Liabilities	$12.07M
Long-Term Debt	$45.15M
Long-Term Liabilities	$45.15M
Total Liabilities	$57.22M
Common Equity	$-31.46M
Tangible Shareholders Equity	$-31.46M
Shareholders Equity	$-31.46M
Common Shares Outstanding	28.68M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-22.18M
Cash Flow from Investing Activities	$-3.19M
Cash Flow from Financial Activities	$28.07M
Beginning Cash	$10.34M
End Cash	$12.92M
Increase/Decrease in Cash	$2.58M
Stock-Based Compensation	$2.22M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.27
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	3.30
Debt to Equity Ratio	-1.43
Gross Margin	56.67%
Operating Margin	-1260.77%
EBIT Margin	-1260.77%
EBITDA Margin	-1206.59%
Pre-Tax Profit Margin	-1238.52%
Profit Margin	-1238.52%
Free Cash Flow	$-25.37M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.16
Inventory Turnover	3.94
Receiveable Turnover	3.59
Days Sales in Receivables	101.53
Return on Equity	159.62%
Return on Tangible Equity	159.62%
Return on Assets	-194.99%
Return on Investments	-367.09%
Book Value Per Share	$-1.10
Free Cash Flow per Share	$-0.83
Operating Cash Flow per Share	$-0.73

Data from Zacks Investment Research, Inc.